AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Orthocellâs single-stage dental implant study has completed treatment of last patient, it is designed to further authenticate the flexibility of CelGro for soft tissue repair and dental bone. To generate further data and educate surgeons on the benefits of using CelGro it represents a key milestone in Orthocellâs marketing strategy. In 2Q CY2019 the release of top line results is expected. The treatment process customarily requires two surgical procedures.
Followed by a second re-entry surgery, to insert the implant support and dental crown, up to 3-6 months later, where patients receive an initial implant placement traditional dental implant procedure are often performed in two-stages. To fill the missing tooth while bone healing is underway patients can be left without a temporary crown which creates challenges for patients both functionally and visually. For some patients advances in technology allow the potential for a single-stage procedure which removes the need for re-entry surgery, potentially reducing the total costs to patients and the health care system and accelerating the healing process.
In in collaboration with leading West Australian oralâs Dr. Brent Allan of St. John of God Subiaco Hospital and maxillofacial surgeon Professor Ming Hao Zheng of the University of Western Australia the single-stage performance study is being undertaken. There are more than 1 million dental implant procedures per year in Italy alone as shown by dental implants are an effective and rapidly growing treatment and industry research, where approximately 60% of procedures require the use of a collagen membrane.
On the solid wharf and integration between the implant and dental bone is on what the success of dental implants relies. In enabling high-quality bone repair and preventing tissue in growth, Celgro plays an important role in this procedure. Celgro assists surgeons in delivering improved patient outcomes via tissue integration qualities, superior handling characteristic and improving bone quality demonstrated by clinical trials compared to the market leading comparative dental product.
To utilize the supplementary marketing data generated from the single-stage performance study and guide superior quality bone formation, Orthocell intends to leverage CelGroâs ability to further position CelGro as the best in class collagen membrane for soft tissue repair and dental bone. The study highlights the potential to extend Orthocellâs innovative dental product range and underpins the versatility and compatibility of CelGro platform technology.
Orthocell Limited (ASX:OCC) traded at a market price of $0.215 as at November 28, 2018 which is near its 52-week low.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.